Liu Yong, He Shun, Zhang Yueming, Dou Lizhou, Liu Xiao, Yu Xinying, Lu Ning, Xue Liyan, Wang Guiqi
Department of Endoscopy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Ann Transl Med. 2021 Feb;9(4):322. doi: 10.21037/atm-20-4265.
Endoscopic submucosal dissection (ESD) and endoscopic mucosal resection (EMR) are used to remove esophagogastric junction (EGJ) neoplasm. This study aimed to compare feasibility, safety, and effectiveness between ESD and EMR to help endoscopists choose treatment methods.
A total of 130 patients with EGJ neoplasm underwent endoscopic resection, including 52 patients with EMR and 78 patients with ESD. Cap-assisted EMR (EMRC) was performed with typical sequences. Larger lesions required removal in multiple pieces (i.e., piecemeal EMR). The ESD procedures were included that marking the periphery of the lesion, submucosa injected, circumferentially cutting and submucosal dissection. Resection time, adverse events, resection rate, R0 resection rate and recurrence rate were compared between the two groups.
There were no significant differences in demographic characteristics or histopathological features between the two groups. Resection time was longer in the ESD group than in the EMR group (64.4±33.9 22.1±8.0 minutes; P<0.01). Adverse events were more common in the ESD group than in the EMR group (16.7% 3.8%; P=0.03), including bleeding (7.7% 3.8%), perforation (5.1% 0%) and stenosis (5.1% 0%). The resection rate and R0 resection rate were much higher in the ESD group than in the EMR group (98.7% and 92.3% 23.1% and 23.1%, respectively; P<0.01). The 5-year overall survival rate and disease-free survival rate were 100% 92.0% and 100% 90.1% between the ESD and EMR groups, respectively (P=0.01 and P=0.01). The 5-year cancer-specific survival rate was 100% 96.0% between the ESD and EMR groups (P=0.08). The recurrence rate was lower in the ESD group than in the EMR group (0% 9.6%; P=0.01).
ESD is an acceptable first-line endoscopic treatment for type II EGJ neoplasm, however, it is time-consuming and has a higher rate of adverse events. Furthermore, EMR is a safe and alternative technique, particularly when EMR could achieve resection.
内镜黏膜下剥离术(ESD)和内镜黏膜切除术(EMR)用于切除食管胃交界部(EGJ)肿瘤。本研究旨在比较ESD和EMR的可行性、安全性和有效性,以帮助内镜医师选择治疗方法。
共有130例EGJ肿瘤患者接受了内镜切除,其中52例行EMR,78例行ESD。采用典型步骤进行帽辅助EMR(EMRC)。较大病变需分块切除(即分块EMR)。ESD手术包括标记病变周边、黏膜下注射、环形切割和黏膜下剥离。比较两组的切除时间、不良事件、切除率、R0切除率和复发率。
两组患者的人口统计学特征或组织病理学特征无显著差异。ESD组的切除时间比EMR组长(64.4±33.9对22.1±8.0分钟;P<0.01)。ESD组的不良事件比EMR组更常见(16.7%对3.8%;P=0.03),包括出血(7.7%对3.8%)、穿孔(5.1%对0%)和狭窄(5.1%对0%)。ESD组的切除率和R0切除率远高于EMR组(分别为98.7%和92.3%对23.1%和23.1%;P<0.01)。ESD组和EMR组的5年总生存率和无病生存率分别为100%对92.0%和100%对90.1%(P=0.01和P=0.01)。ESD组和EMR组的5年癌症特异性生存率分别为100%对96.0%(P=0.08)。ESD组的复发率低于EMR组(0%对9.6%;P=0.01)。
ESD是II型EGJ肿瘤可接受的一线内镜治疗方法,然而,它耗时且不良事件发生率较高。此外,EMR是一种安全的替代技术,尤其是当EMR能够实现切除时。